Drug intelligence / Profile preview

mifepristone + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of mifepristone, a glucocorticoid receptor antagonist, and pembrolizumab, an immune checkpoint inhibitor. The combination is being investigated for the treatment of advanced HER2-negative breast cancer. The rationale is that pretreatment with mifepristone may shift the cytotoxic immune response toward Th1, potentially enhancing response to pembrolizumab.

Brand names: KeytrudaKorlymMifeprex
Other names: pembrolizumab and mifepristone

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on mifepristone + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mifepristone + pembrolizumab.

Explore the full profile